RedHill Biopharma (NASDAQ:RDHL) Earns Hold Rating from Analysts at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of RedHill Biopharma (NASDAQ:RDHL) in a report released on Friday. The firm set a “hold” rating on the biotechnology company’s stock.

RedHill Biopharma Price Performance

NASDAQ RDHL opened at $6.54 on Friday. The company’s 50 day moving average is $6.82 and its 200-day moving average is $60.27. RedHill Biopharma has a 12-month low of $5.41 and a 12-month high of $31.50.

Institutional Investors Weigh In On RedHill Biopharma

A hedge fund recently bought a new stake in RedHill Biopharma stock. GAMMA Investing LLC acquired a new stake in shares of RedHill Biopharma Ltd. (NASDAQ:RDHL) during the fourth quarter, according to its most recent filing with the SEC. The fund acquired 5,089 shares of the biotechnology company’s stock, valued at approximately $32,000. GAMMA Investing LLC owned 0.40% of RedHill Biopharma as of its most recent filing with the SEC. Hedge funds and other institutional investors own 7.20% of the company’s stock.

About RedHill Biopharma

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.